Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I<sup>131 </sup>KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I<sup>131 </sup>KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

<p>Abstract</p> <p>Background</p> <p>Advanced pancreatic cancer has a poor prognosis, and the current standard of care (gemcitabine based chemotherapy) provides a small survival advantage. However the drawback is the accompanying systemic toxicity, which targeted treatm...

Full description

Bibliographic Details
Main Authors: Bosonnet Lorraine, Chauhan Seema, Lane Steven, Smith Catrin, Evans Jonathan E, Vinjamuri Sobhan, Raraty Michael GT, Shore Susannah, Sultana Asma, Garvey Conall, Sutton Robert, Neoptolemos John P, Ghaneh Paula
Format: Article
Language:English
Published: BMC 2009-02-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/9/66

Internet

http://www.biomedcentral.com/1471-2407/9/66

Similar Items